Abbott Laboratories (ABT) - NYSE
  • Jan. 3, 2013, 5:08 PM

    Abbott Labs (ABT), Johnson & Johnson (JNJ) and Sanofi (SNY) have all displayed an interest in Warburg Pincus' Bausch & Lomb. Warburg, working through Goldman Sachs (GS), is hoping to get at least $10B for the business and is seeking first-round bids by month’s end. The $10B price tag would be a major coup for Warburg, raking in a 200% return off its $1.7b equity investment.

    | Jan. 3, 2013, 5:08 PM | 1 Comment
  • Jan. 3, 2013, 9:00 AM

    Abbott Labs (ABT +0.5%) launches its XIENCE Xpedition drug-eluting coronary stent, which slowly releases a medicine to block cell proliferation, after receiving FDA approval for the device. "XIENCE Xpedition represents a powerful combination of deliverability, strong clinical data and broad availability of meaningful sizes," says Dr Samin Sharma of Mount Sinai Medical Center in New York. (PR)

    | Jan. 3, 2013, 9:00 AM
  • Jan. 3, 2013, 8:28 AM

    BG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first automated version of the company's Galectin-3 blood test for improving the management of heart conditions. BG is working with four partners to commercialize the test, including Abbott Labs (ABT) and Siemens (SI). The EU approval comes just a week after SA author Robert Fabian called BG Medicine a "hidden gem." (PR)

    | Jan. 3, 2013, 8:28 AM
  • Jan. 3, 2013, 4:35 AM

    AbbVie (ABBV) closed at $35.12 yesterday after opening at $34.40 following its spin-off from Abbott Labs (ABT), giving it a market cap of $55.8B vs Abbott's $50.7B. AbbVie faces plenty of challenges, not least reducing its dependence on its $9B-per-year arthritis treatment Humira, which accounts for at least 70% of the company's profit but which will lose its patent protection in 2017.

    | Jan. 3, 2013, 4:35 AM
  • Jan. 2, 2013, 12:45 PM
    Midday top 10 gainers: ZIP +48%. BIOF +28%. STXS +25%. GIGA +21%. FORD +19%. IQNT +20%. EGLE +18%. OTT +18%. GEVO +17%. APAGF +17%.
    Midday top 10 Losers: ABT -51%. SKUL -14%. DOLE -13%. TRIT -12%. ATAI -12%. HMNY -9%. CHRM -9%. NTLS -9%. VSCI -8%. MR -8%.
    | Jan. 2, 2013, 12:45 PM | 2 Comments
  • Jan. 2, 2013, 9:10 AM
    Premarket gainers: ZIP +47.94%. POL +18.71%. SGYP +16.92%. MCP +9%. JRCC +8.41%. PAL +7.69%. KWK +7.69%. ZGNX +7.52%. PPHM +6.82%. ONTY +6.77%.
    Losers: ABT -50%.
    | Jan. 2, 2013, 9:10 AM | 6 Comments
  • Jan. 2, 2013, 8:55 AM

    Abbott Labs (ABT) completes the separation of AbbVie (ABBV), its R&D-based pharmaceuticals business that will start trading on the NYSE today. Wells Fargo maintains an "Outperform" rating on Abbott's shares, citing the company's above-average growth outlook and opportunities to significantly increase its margin. Wells Fargo sets Abbott a price target of $33-$34; its shares are $32.25 premarket.(PR)

    | Jan. 2, 2013, 8:55 AM
  • Dec. 31, 2012, 4:50 PM

    AbbVie (ABBV) is set to replace Dell (DELL) in the S&P 100, and Federated Investors (FII) in the S&P 500 today. Additionally, Federated will replace ITT Educational Services (ESI) in the S&P MidCap 400, and ITT Educational Services will replace NCI Inc. (NCIT) in the S&P SmallCap 600. Abbott Laboratories (ABT) is spinning off AbbVie (ABBV) in a transaction expected to be completed today. (PR)

    | Dec. 31, 2012, 4:50 PM | 3 Comments
  • Dec. 31, 2012, 9:00 AM

    Not all diagnostics companies are worried at the prospect of the Supreme Court striking down patents on two cancer-related genes "owned" by Myriad (MYGN) in a decision that is due to come in 2013. Quest (DGX) says it could be a "positive development," as it would "open new opportunities to develop new testing services." Myriad, which has spent 17 years and $500M on isolating the "DNA molecules and processes," isn't so sanguine.

    | Dec. 31, 2012, 9:00 AM
  • Dec. 21, 2012, 6:57 AM
    DELL is off 1.9% premarket after being removed from the S&P 100 last evening. With a market cap below $18.5B, "it is no longer representative of the mega-cap market space." The company will be replaced in the index by Abbot Labs (ABT).
    | Dec. 21, 2012, 6:57 AM
  • Dec. 14, 2012, 1:59 PM
    Abbott Laboratories (ABT) declares quarterly dividend of $0.14/share post-split. The AbbVie board intends to declare dividend of $0.40/share totaling dividend to $0.54/share, 6% increase from prior dividend of $0.51, representing an annual yield of 3.31%. The quarterly dividend of $0.14/share will be payable on Feb. 15, to shareholders on record of Jan. 15. (PR)
    | Dec. 14, 2012, 1:59 PM | 5 Comments
  • Dec. 13, 2012, 9:47 AM

    A blood test that Abbott Labs (ABT -0.4%) is developing could cut the time it takes to diagnose a heart attack by several hours, a small study of 19 healthy people indicates. The test assesses the blood for troponin, which is a protein in the heart muscle and which can indicate injury to the organ. (PR)

    | Dec. 13, 2012, 9:47 AM
  • Dec. 13, 2012, 4:21 AM

    AstraZeneca's (AZN -1.6% in London) fostamatinib pill was inferior to Abbott Labs' (ABT) Humira in controlling rheumatoid arthritis symptoms in a Phase II trial. AstraZeneca can still pin its hopes, though, on a Phase III study in which fostamatinib is being given with other drugs. Results are due out in H1 next year. (PR)

    | Dec. 13, 2012, 4:21 AM | 1 Comment
  • Dec. 11, 2012, 6:48 PM
    Goldman Sachs (GS) gets the nod by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division. Warburg is said to be seeking at least $10B for the business. According to reports, Goldman has already contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbott Laboratories (ABT) will be among the other companies contacted.
    | Dec. 11, 2012, 6:48 PM
  • Dec. 11, 2012, 4:06 AM
    Abbott Laboratories' (ABT) AbbVie spin-off is worth more than Abbott ahead of the official split of the company in January. "When issued" trading in the two entities began yesterday in the secondary market, with the new Abbott valued at $47.9B and AbbVie $55.3B. The market cap of the combined Abbott is $103.27B.
    | Dec. 11, 2012, 4:06 AM | 5 Comments
  • Dec. 9, 2012, 2:27 AM

    The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous)

    | Dec. 9, 2012, 2:27 AM | 1 Comment
Company Description
Abbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products. The company operates through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products.... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States